Formula I Compounds for Small-Molecule PD-1/PD-L1 Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for treating cancer, HIV, and HBV are limited by the suppression of immune responses due to the PD-1/PD-L1 interaction, leading to T cell exhaustion and dysfunction, necessitating the development of small molecule agents that can effectively inhibit this interaction.
Innovation Solution
Development of small molecule compounds that act as inhibitors of PD-1, PD-L1, or the PD-1/PD-L1 interaction, capable of restoring and augmenting T cell activation and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to block PD-1/PD-L1 interaction, then T cell activation is restored and immune response is enhanced, but the complexity of the therapeutic agent increases and manufacturing cost rises
Solution Approach 1:
The patent replaces the biological/macromolecular mechanism of monoclonal antibodies with a chemical/small molecule mechanism. The small molecule compounds (Formula I) provide PD-1/PD-L1 blockade through chemical interaction rather than through the complex biological mechanism of antibody binding, thereby reducing therapeutic complexity while maintaining T cell activation effects
Solution Approach 2:
The patent changes the fundamental parameter of the therapeutic agent from macromolecular (antibody) to molecular (small compound). This parameter change reduces the complexity, size, and manufacturing complexity of the therapeutic agent while preserving the ability to block PD-1/PD-L1 interaction and restore T cell function
2Ease of manufacture
If small molecule compounds are developed to inhibit PD-1/PD-L1 interaction, then ease of manufacture improves and cost decreases, but the precision and specificity of the interaction blockade must be maintained
Solution Approach 1:
The patent changes the scale of the therapeutic agent from macromolecular to molecular, which inherently improves manufacturability and reduces production complexity. The small molecule compounds can be synthesized through established organic chemistry routes, enabling easier manufacturing and lower costs while maintaining specific biological activity
Solution Approach 2:
The patent creates simplified molecular models (small compounds) that replicate the functional capability of the complex natural system (PD-1/PD-L1 interaction). These small molecules serve as simplified versions that achieve the same biological effect with reduced complexity, analogous to creating a model that copies essential functions while eliminating unnecessary complexity
3Reliability
If chronic antigen stimulation occurs during tumor disease or chronic infections, then T cells express elevated levels of PD-1 and become dysfunctional, but blocking PD-1/PD-L1 interaction restores T cell activity
Solution Approach 1:
The patent applies preliminary anti-action by using small molecule compounds to block the PD-1/PD-L1 interaction before T cell exhaustion can fully develop or to reverse exhaustion when it occurs. The compounds prevent the harmful interaction that causes T cell dysfunction, thereby preserving or restoring T cell activity in chronic infection and tumor settings
Data Source
AI summary
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.